A functional genomic screen in mesothelioma uncovered that loss of function of BRCA1-associated protein 1 (BAP1) is associated with vulnerability to ribonucleotide reductase (RNR) inhibitors such as gemcitabine [52]. This evidence concerns the gene BAP1 and mesothelioma.